β-Antithrombin, subtype of antithrombin deficiency and the risk of venous thromboembolism in hereditary antithrombin deficiency: A family cohort study

TEMPORARY REMOVAL: Direct oral anticoagulants in antithrombin deficiency: initial experience in a single center

“…AT deficiency is associated with an increased risk of recurrent VTE. In family studies, the annual incidence of recurrent VTE is estimated to be around 10% without long term anticoagulation therapy 2,8,9 with the incidence accumulating up to 50% during ten years of follow-up 10 With long term anticoagulation therapy the recurrence risk in AT deficient patients is effectively decreased to 1.5 to 4.0% per year. 2,8,11,12 Based on this , we treat AT deficiency patients with long term anticoagulation therapy after a first VTE event, in the absence of an increased bleeding risk.…”

“…In family studies, the annual incidence of recurrent VTE is estimated to be around 10% without long term anticoagulation therapy 2,8,9 with the incidence accumulating up to 50% during ten years of follow-up 10 With long term anticoagulation therapy the recurrence risk in AT deficient patients is effectively decreased to 1.5 to 4.0% per year. 2,8,11,12 Based on this , we treat AT deficiency patients with long term anticoagulation therapy after a first VTE event, in the absence of an increased bleeding risk. Data stratified by the presence of a provoking factor is thus far not available for the population of AT deficiency patients, specifically because of the small numbers included in studies concerning these patients.…”

Direct Oral Anticoagulants in Antithrombin Deficiency: Initial Experience in a Single Center

“…Seven out of 10 patients were included in previous family studies. 2 Reasons for switch to rivaroxaban were unstable VKA therapy and medication convenience. None of the patients experienced recurrent venous thrombotic disease (95% confidence interval [CI] 0-45%) and no major bleeds did occur during treatment with rivaroxaban.…”

“…AT deficiency is associated with an increased risk of recurrent VTE. In family studies, the annual incidence of recurrent VTE is estimated to be around 10% without longterm anticoagulation therapy 2,8,9 with the incidence accumulating up to 50% during 10 years of follow-up. 10 With long-term anticoagulation therapy the recurrence risk in ATdeficient patients is effectively decreased to 1.5 to 4.0% per year.…”

“…10 With long-term anticoagulation therapy the recurrence risk in ATdeficient patients is effectively decreased to 1.5 to 4.0% per year. 2,8,11,12 Based on this, we treat AT deficiency patients with long-term anticoagulation therapy after a first VTE event, in the absence of an increased bleeding risk. Data stratified by the presence of a provoking factor is thus far not available for the population of AT deficiency patients, specifically because of the small numbers included in studies concerning these patients.…”